Shanghai - Delayed Quote CNY

CHINA NATIONAL MEDICINE (600511.SS)

30.50
-0.29
(-0.94%)
At close: 3:00:01 PM GMT+8
Loading Chart for 600511.SS
  • Previous Close 30.79
  • Open 30.68
  • Bid 30.50 x --
  • Ask 30.51 x --
  • Day's Range 30.21 - 30.78
  • 52 Week Range 27.12 - 38.00
  • Volume 3,589,036
  • Avg. Volume 4,329,517
  • Market Cap (intraday) 23.012B
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) 11.51
  • EPS (TTM) 2.65
  • Earnings Date --
  • Forward Dividend & Yield 0.85 (2.80%)
  • Ex-Dividend Date Jun 13, 2024
  • 1y Target Est --

China National Medicines Corporation Ltd., together with its subsidiaries, distributes pharmaceutical products in China. The company also manufactures and sells new drugs and finished drugs; sells Chinese patent medicines and western medicines, and medical equipment; and offers warehousing and import and export agency services. It serves hospitals, retail pharmacies, and medical institutions. The company was founded in 1999 and is based in Beijing, China.

www.cncm.com.cn

3,104

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600511.SS

View More

Performance Overview: 600511.SS

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600511.SS
10.87%
SSE Composite Index (000001.SS)
0.85%

1-Year Return

600511.SS
9.41%
SSE Composite Index (000001.SS)
7.02%

3-Year Return

600511.SS
15.88%
SSE Composite Index (000001.SS)
7.42%

5-Year Return

600511.SS
18.80%
SSE Composite Index (000001.SS)
20.13%

Compare To: 600511.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600511.SS

View More

Valuation Measures

Annual
As of 5/22/2025
  • Market Cap

    23.01B

  • Enterprise Value

    15.02B

  • Trailing P/E

    11.51

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.45

  • Price/Book (mrq)

    1.31

  • Enterprise Value/Revenue

    0.29

  • Enterprise Value/EBITDA

    5.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.91%

  • Return on Assets (ttm)

    3.87%

  • Return on Equity (ttm)

    11.31%

  • Revenue (ttm)

    51.19B

  • Net Income Avi to Common (ttm)

    2B

  • Diluted EPS (ttm)

    2.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.85B

  • Total Debt/Equity (mrq)

    4.41%

  • Levered Free Cash Flow (ttm)

    -439.49M

Research Analysis: 600511.SS

View More

Company Insights: 600511.SS

Research Reports: 600511.SS

View More

People Also Watch